ERBB2 and prostate carcinoma: Candidates such as TVB316 and TVB2640 have been demonstrated to be effective and less toxic than their predecessors, and more than 10 clinical trials of TVB2640 for the treatment of NSCLC, prostate cancer, and HER2-positive metastatic breast cancer are underway (NCT03808558, NCT03179904, and NCT05743621).